Curiox reports lower operator- and site-dependent variability with automated antibody cocktailing at ICCS 2026
Summary
Curiox reports ICCS 2026 poster data on the Pluto Antibody Cocktailing Wizard across 9-, 10- and 24-colour panels. The company reports lower operator/site variability and reduced hands-on time. CFCM publishes the signal as WATCH because the evidence is manufacturer-generated poster data rather than independent clinical validation.
The evidence
Curiox has published a poster landing page for ICCS 2026 evaluating its Pluto Antibody Cocktailing Wizard across 9-, 10- and 24-colour panels. The company reports that five of six markers were at or below 5% CV, hands-on time fell from 6:26 manually to 3:18–4:34 with automation, cross-site vial-to-vial CV was 0.4% automated versus 1.9% manual, and concordance was r=0.997.
CFCM explainer — what is being tested
Manual antibody cocktail preparation → operator/site variability → automated cocktailing with Pluto ACW → reported reduction in preparation variability.
Source/credit: CFCM explainer based on Curiox's ICCS 2026 poster landing page. These are manufacturer-generated poster data, not independently reviewed clinical-performance evidence.
Interpretation and limitations
The numerical results are published by the manufacturer and need review of the complete poster methods, replicate structure, statistical analysis, instrument/reagent controls and clinical relevance before CFCM treats them as robust comparative evidence. The annual meeting runs 4–6 October, so the data are online before the scheduled meeting presentation. Reduced cocktail-preparation variability does not itself establish improved patient-level diagnostic accuracy or full end-to-end assay reproducibility.
What this means for laboratories
Antibody master-mix preparation is an under-discussed source of pre-analytical variability in high-parameter flow. Curiox's poster provides quantitative evidence that automated cocktailing can reduce preparation variability and hands-on time in the tested workflows. CFCM publishes this as WATCH: the reported numbers are useful, but they do not by themselves establish patient-level diagnostic benefit or end-to-end assay equivalence.
Source Date
Event date
Commercial Regulatory Status
Existing Curiox Pluto automation platform. This record concerns new manufacturer-generated performance data, not a new regulatory authorization or product launch.
Primary source
Read the source →An announcement is not proof of availability or authorisation. Interpret status within the stated jurisdiction and evidence boundary.
Editor and independence disclosure →CFCM WEEKLY · EVERY SUNDAY
The science behind the signal, in your inbox.
Get evidence-led clinical flow cytometry news, original conference posters, figures from published papers, practical learning pills, an advanced quiz and the story of one CD marker each week. Free. No spam.
Get CFCM Weekly →Complete the form and confirm the email we send you. Unsubscribe any time. Privacy policy.